Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma

Rajendra, Shanmugarajah

doi:10.1016/j.hoc.2017.01.003

Cited by 7 publications

(5 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies show that esophageal cancer patients hold a 5-year survival rate of only 18.8% [ 1 ]. The primary premalignant cause of reaching esophageal malignancy is Barrett’s esophagus (BE) [ 2 , 3 ], where the development of healthy cells in the esophagus lining into columnar mucosa through metaplastic change leads to EAC [ 4 ]. The early detection and treatment of EAC may help in increasing the survival chance of the patient [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Early esophageal adenocarcinoma detection using deep learning methods

Ghatwary

Zolgharni

2019

Int J CARS

View full text Add to dashboard Cite

PurposeThis study aims to adapt and evaluate the performance of different state-of-the-art deep learning object detection methods to automatically identify esophageal adenocarcinoma (EAC) regions from high-definition white light endoscopy (HD-WLE) images.MethodSeveral state-of-the-art object detection methods using Convolutional Neural Networks (CNNs) were adapted to automatically detect abnormal regions in the esophagus HD-WLE images, utilizing VGG’16 as the backbone architecture for feature extraction. Those methods are Regional-based Convolutional Neural Network (R-CNN), Fast R-CNN, Faster R-CNN and Single-Shot Multibox Detector (SSD). For the evaluation of the different methods, 100 images from 39 patients that have been manually annotated by five experienced clinicians as ground truth have been tested.ResultsExperimental results illustrate that the SSD and Faster R-CNN networks show promising results, and the SSD outperforms other methods achieving a sensitivity of 0.96, specificity of 0.92 and F-measure of 0.94. Additionally, the Average Recall Rate of the Faster R-CNN in locating the EAC region accurately is 0.83.ConclusionIn this paper, recent deep learning object detection methods are adapted to detect esophageal abnormalities automatically. The evaluation of the methods proved its ability to locate abnormal regions in the esophagus from endoscopic images. The automatic detection is a crucial step that may help early detection and treatment of EAC and also can improve automatic tumor segmentation to monitor its growth and treatment outcome.

show abstract

Section: Introductionmentioning

confidence: 99%

Early esophageal adenocarcinoma detection using deep learning methods

Ghatwary

Zolgharni

2019

Int J CARS

View full text Add to dashboard Cite

show abstract

“…2 BE is the strongest known risk factor for development of esophageal adenocarcinoma (EAC). 3 Studies have proposed a multistep pathway, the metaplasia-dysplasia-adenocarcinoma sequence, for the development of esophageal cancer. 4 The increasing incidence of EAC over the last few decades is worrisome.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Cryotherapy as a Primary Endoscopic Ablation Modality for Dysplastic Barrett’s Esophagus and Early Esophageal Neoplasia: A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Introduction: Cryotherapy is a cold-based ablative therapy used primarily as second line therapy in patients with Barrett’s esophagus (BE) who have persistent dysplasia after undergoing endoscopic treatment with radiofrequency ablation (RFA). Few studies have described the use of cryotherapy as a primary treatment modality for dysplastic or neoplastic BE. Aim: To evaluate the efficacy of cryotherapy as primary treatment of dysplastic and/or neoplastic BE by conducting a systemic review and meta-analysis. Methods: A systematic search of Medline, Embase, and Web of Science was performed from January 2000 through March 2020. Articles included were observational studies and clinical trials which included patients who had biopsy confirmed dysplastic or neoplastic BE (i.e., high grade dysplasia (HGD), low grade dysplasia (LGD) or intramucosal adenocarcinoma (ImCA)), underwent ≥1 session of cryotherapy, and had a follow-up endoscopy. Primary outcomes were pooled proportions of patients achieving complete eradication of dysplasia (CE-D) and/or intestinal metaplasia (CE-IM) by using a random effects model. Results: Fourteen studies making up 405 patients with follow-up ranging from 3-54 months were included. In 13 studies, a total of 321/405 patients achieved CE-D with a pooled proportion of 84.8% (95% confidence interval [CI] 72.2-94.4), with substantial heterogeneity (I2 = 88.3%). In 13 studies, a total of 321/405 patients achieved CE-D with a pooled proportion of 84.8% (95% confidence interval [CI] 72.2-94.4), with substantial heterogeneity (I2 = 88.3%). Subgroup analysis of only high-quality studies revealed a pooled proportion of CE-D 91.3% (95% CI, 83.0-97.4, I2 = 69.5%) and pooled proportion of CE-IM of 71.6% (95% CI, 59.0-82.9, I2 = 80.9%). Adverse events were reported in 12.2% patients. Conclusion: Cryotherapy is a safe and effective primary therapy for dysplastic/early neoplastic BE. CE-D and CE-IM rates are comparable to those for other ablation modalities, including RFA. Cryotherapy should be considered for primary therapy of dysplastic BE and early esophageal neoplasia.

show abstract

“…Due to the special anatomical site, it was difficult to the difference between BE and cardiac intestinal change [6]. It was not always perfectly match of squamous-columnar border with esophageal gastric junction by endoscopy [7], and there was lack of identification basis for distinguish of SSBE and gastric mucosa intestinal metaplasia. The aim of this study was to clarify the molecular mechanism of BE carcinogenesis from epigenetics, and to provide certain theoretical basis for diagnosis and treatment of BE carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter

Li¹

2019

CMR

View full text Add to dashboard Cite

This study was designed to explore the role of MiR203 promoter methylation in the process of Barrett's esophagus carcinogenesis. RT-PCR was used to detect the expression levels of miRNA-203 in Barrett's esophagus, esophageal cancer and normal esophageal mucosa cell lines, before and after the treatment of demethylation. MiR203 promoter methylation levels in these cell lines were measured by Methylation Specific PCR (MSP). Immunohistochemistry was used to test the expression and distribution of K-Ras, a target of miR203, in esophageal cancer, BE and normal esophagus tissues. The following results were found based on the above methods. MiR203 expression levels were reduced obviously in Barrett esophagus and esophageal cancer cells than normal esophageal cells, the difference was statistically significant (P=0.003). After demethylation treatment, miR203 expression levels were significantly increased in Barrett's esophagus and esophageal cancer cells, the differences were statistically significant (P=0.03). MSP results showed that miR203 promoter changed to be low-methylation or non-methylation after demethylation treatment. In conclusion, MiR203 in Barrett's esophagus and esophageal cancer cells reduced expression is related to its Promoter methylation, miR203 promoter methylation throughout the carcinogenesis of Barrett's esophagus, it may become a key molecular biomarker in process of Barrett esophagus cancerous, and may become the prevention and treatment targets of Barrett esophagus carcinogenesis.

show abstract

Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma

Cited by 7 publications

References 113 publications

Early esophageal adenocarcinoma detection using deep learning methods

Early esophageal adenocarcinoma detection using deep learning methods

Efficacy of Cryotherapy as a Primary Endoscopic Ablation Modality for Dysplastic Barrett’s Esophagus and Early Esophageal Neoplasia: A Systematic Review and Meta-Analysis

MiR203 Lost Suppressor Genes Function in the Process of Barrett’s Esophagus Carcinogenesis Because of High Methylation in Promoter

Contact Info

Product

Resources

About